Introduction Psoriasis prevalence in the elderly is growing. It is estimated that 15% of elderly
psoriasis patients suffer from moderate-to-severe disease, thus requiring systemic …

Biological therapy has revolutionized moderate to severe psoriasis treatment. However,
despite being more effective than conventional systemic treatments, some patients do not …

Background Psoriasis is a common inflammatory disease in any age group, but also in older
patients (≥ 65 years of age). Since older patients are often excluded from clinical trials …

With our aging population, an increasing number of psoriasis patients are classified as
elderly. However, psoriasis treatment in older adults can be challenging, given an increased …

Introduction: The treatment of psoriasis with conventional topical therapies and disease-
modifying anti-rheumatic drugs (DMARDs) is often linked to unsatisfactory outcomes and the …

The number of elderly people with chronic inflammatory rheumatic diseases is increasing.
This heterogeneous and comorbid population is at particular risk of cardiovascular …

Background Safety and efficacy of new treatments are analyzed in clinical trials but their
capacity to show potential effects of long‐term treatment and more than short latency of …

Background and objectives Since its inception, the Psoriasis Group (GPs) of the Spanish
Academy of Dermatology and Venereology (AEDV) has worked to continuously update …

Background Information on the safety of tumour necrosis factor (TNF) antagonists frequently
arises from their use in rheumatic diseases, their first approved indications, and is later …

Justificación y objetivos El desarrollo del actual arsenal terapéutico fundamentado en las
terapias biológicas, la experiencia acumulada en ensayos clínicos y en práctica clínica real …